awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42336339-EC5A6702-E725-4005-A24D-03B3D1BB0C38
Q42336339-EC5A6702-E725-4005-A24D-03B3D1BB0C38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42336339-EC5A6702-E725-4005-A24D-03B3D1BB0C38
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
P2860
Q42336339-EC5A6702-E725-4005-A24D-03B3D1BB0C38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42336339-EC5A6702-E725-4005-A24D-03B3D1BB0C38
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b5d9e1151e3fea10492823ce305a41f07ed9c341
P2860
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.